VIL ONGOING RELATIONSHIP WITH SPROUT FUNDS Since 2005, the Fund Managers have managed the remaining portfolio of healthcare technology investments in Sprout Capital VU, L.P., Sprout Capital VII, L.P., and Sprout Capital IX, L.P. under a Sub-Management Agreement between Credit Suisse and New Leaf Venture Partners, L.L.C. (the “Management Company”). In return for these management services, the Management Company had received a portion of the management fee collected by those Sprout funds related to the healthcare portfolio. At the present time, Sprout Capital IX, L.P. is the only fund with any remaining active healthcare technology investments. There were six active health care technology companies (three board seats) in the Sprout Capital IX, L.P. portfolio that are managed by the Fund Managers, which represented $68 million of carrying value as of March 31, 2014. These remaining investments are in mature companies and the Fund Managers intend to continue to manage the investments with an emphasis on finding exit opportunities for each company at an appropriate time. The Fund Managers have already exited a portion of these companies in early 2014, leaving a very limited tail of Sprout investments and board seats. The Fund Managers expect the arrangement with Credit Suisse to continue for the foreseeable future, but the Management Company no longer receives any management fees for these services. The Sub-Management Agreement between Credit Suisse and the Management Company will wind down and eventually be terminated as the investments in the Sprout Capital IX, L.P. portfolio are exited. 45 CONTROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024056